ATR 107

Drug Profile

ATR 107

Alternative Names: ATR-107; PF-05230900

Latest Information Update: 14 Nov 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Pfizer; Wyeth
  • Class Anti-inflammatories
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Crohn's disease; Systemic lupus erythematosus

Most Recent Events

  • 01 Nov 2011 Discontinued - Phase-I for Crohn's disease in USA (IV)
  • 01 Nov 2011 Discontinued - Phase-I for Crohn's disease in USA (SC)
  • 09 Jun 2010 Phase-I clinical trials in Crohn's disease in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top